These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20649640)

  • 1. Advanced glycation end-products and the kidney.
    Busch M; Franke S; Rüster C; Wolf G
    Eur J Clin Invest; 2010 Aug; 40(8):742-55. PubMed ID: 20649640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products and the kidney.
    Bohlender JM; Franke S; Stein G; Wolf G
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F645-59. PubMed ID: 16159899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.
    Wu L; Ma L; Nicholson LF; Black PN
    Respir Med; 2011 Mar; 105(3):329-36. PubMed ID: 21112201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies.
    Daroux M; Prévost G; Maillard-Lefebvre H; Gaxatte C; D'Agati VD; Schmidt AM; Boulanger E
    Diabetes Metab; 2010 Feb; 36(1):1-10. PubMed ID: 19932633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.
    Jensen LJ; Østergaard J; Flyvbjerg A
    Horm Metab Res; 2005 Apr; 37 Suppl 1():26-34. PubMed ID: 15918107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation end-products in diabetes mellitus, with particular reference to angiopathy.
    Chiarelli F; Mansour M; Verrotti A
    Diabetes Nutr Metab; 2000 Aug; 13(4):192-9. PubMed ID: 10961486
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
    Kanková K
    Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats.
    Kim YS; Kim NH; Lee SW; Lee YM; Jang DS; Kim JS
    Eur J Pharmacol; 2007 Aug; 569(3):171-9. PubMed ID: 17597607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases.
    Saito A; Takeda T; Sato K; Hama H; Tanuma A; Kaseda R; Suzuki Y; Gejyo F
    Ann N Y Acad Sci; 2005 Jun; 1043():637-43. PubMed ID: 16037287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
    Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
    Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
    Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
    Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing.
    Yan SF; Yan SD; Herold K; Ramsamy R; Schmidt AM
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):511-24, viii. PubMed ID: 16959583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
    Liu IM; Tzeng TF; Liou SS; Chang CJ
    J Ethnopharmacol; 2009 Jul; 124(2):211-8. PubMed ID: 19397971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
    Park L; Raman KG; Lee KJ; Lu Y; Ferran LJ; Chow WS; Stern D; Schmidt AM
    Nat Med; 1998 Sep; 4(9):1025-31. PubMed ID: 9734395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycation in diabetic nephropathy.
    Forbes JM; Cooper ME
    Amino Acids; 2012 Apr; 42(4):1185-92. PubMed ID: 20963456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.